It was patented in 1976 and approved for medical use in 1987.[3]
Medical uses
Second generation cephalosporins are more effective in treating Gram-negative bacilli compared to first generation cephalosporins, which have a greater coverage for Gram-positive cocci. Also, it has been reported that cefuroxime is resistant to hydrolysis by β-lactamases produced by Gram-negative bacteria.[4]
Cefuroxime axetil treats infections against methicillin-, oxacillin- and penicillin-sensitive bacterial strains.[7] Cefuroxime axetil does not work against enterococci. [5]
Cefuroxime axetil is a second generation cephalosporin that, like penicillins antibiotics, contains a β-lactam ring structure. Cephalosporins work as bactericidal antibiotics; that by binding to penicillin-binding proteins (PBPs), inhibit the last step of the bacterial cell wall synthesis. Once the β-lactam ring binds to PBPs, cross-linking between peptidoglycan units is inhibited.[4]
Pharmacokinetics
Absorption: Once consumed, cefuroxime axetil is converted to the active compound cefuroxime by esterases of mucosal cells in the gastrointestinal tract. Cefuroxime is then released for systematic circulation. If cefuroxime axetil is given with food, absorption values can increase from 37% in fasting patients to 52% in fed patients.[5]
Distribution: It has been reported that after cefuroxime axetil administration, it can be found in tonsil tissue, sinus tissue, bronchial tissue and middle ear effusion.[5]
Elimination: After cefuroxime production, the body is unable to metabolize the drug, and is eliminated unchanged in the urine.[5]
History
It was discovered by Glaxo (now GlaxoSmithKline) and introduced in 1987.[8] It was approved by FDA on December 28, 1987.[9] It is available by GSK as Ceftin in the US[10] and Ceftum in India.[11]